Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

Inclusion Criteria: * PRE-REGISTRATION INCLUSION * Able to understand and willingness to sign a written informed consent document and follow study procedures * Willing to abstain from grapefruit juice during study * Willing to employ adequate contraception for men and women of childbearing potential; Note: acceptable methods include double barrier methods, intrauterine device (IUD), postmenopausal status documented by serum follicle stimulating hormone (FSH), and/or documentation of surgical sterilization * Willing to provide blood and tissue specimens for research purposes * REGISTRATION INCLUSION * Normal organ function and have normal laboratory findings without clinically significant findings * Leukocytes \>= 3 x 10\^3/microliter (B/L) * Absolute neutrophil count \>= 1.5 x 10\^3/microliter (B/L) * Platelets \>= 100 x 10\^3/microliter (B/L) * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 x institutional upper limit of normal (ULN) * Creatinine =\< institutional upper limit of normal * Body mass index \< 35 kg/m\^2 * No findings in the rectum of advanced adenoma, chronic inflammation, or cancer Exclusion Criteria: * PRE-REGISTRATION EXCLUSION * Documented history of advanced adenomas (\>= 1 cm in maximal diameter, \>= 3 in total number, villous morphology, or high-grade dysplasia) or colorectal cancer * Family history of polyposis syndrome (e.g., familial adenomatous polyposis \[FAP\], hereditary nonpolyposis colorectal cancer \[HNPCC\]) or colorectal cancer (first degree relatives younger than 60 years old) * History of gastroparesis * History of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery; exception: prior appendectomy \>= 60 days prior to pre-registration is not an exclusion criterion * History of celiac disease * Inflammatory bowel disease (Crohn's disease, ulcerative colitis) * Previous diagnosis of irritable bowel syndrome, chronic constipation, functional bowel disorders, colonic motility disorder, or opioid-induced constipation * Any malignancy within 3 years of baseline; exception: participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator * Currently receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to dolcanatide or to any of the excipients * History of difficulty with sigmoidoscopy or abnormal colorectal anatomy * Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or lactating women * Current use of laxatives more than 3 times per week * Current use of \>= 5 cigarettes/day * Current use of \>= 3 alcoholic drinks/day * Use of anti-coagulants or anti-platelet agents within 5 days prior to anticipated sigmoidoscopy; exception: individuals taking aspirin will not be excluded and will not be subject to a wash-out period * History of bleeding/coagulation problems * Any medical condition reported by the participant or documented in the medical record that is judged by the investigator to constitute a risk to safe participation * Known or suspected mechanical gastrointestinal obstruction * REGISTRATION EXCLUSION * Sigmoidoscopy finding requiring clinical intervention * Use of any illicit or illegal substances detected by urinary drug screen